GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
GH Research PLC welcomes the White House Executive Order aimed at speeding up the development and patient access to innovative therapies for serious mental illnesses, including psychedelic treatments. The company is advancing its proprietary inhaled mebufotenin candidate, GH001, toward a global pivotal Phase 3 trial for treatment-resistant depressi…